Profitable, expanding globally, and facing a GLP-1 transition
- The company reported $126.0 million of net income in 2024, proving its original subscription model can scale profitably.
- Hims shifted to reporting United States and Rest of World revenue after its $1.15 billion acquisition of Eucalyptus.
- The FDA resolved the semaglutide shortage in February 2025, forcing a pivot to 503A compounding and branded GLP-1 partnerships.
- The product mix now includes proactive care like hormone therapy and comprehensive lab testing to boost subscriber loyalty.
- The stock story depends heavily on whether global expansion and branded weight loss options can maintain the company's high historical margins.
A global shift beyond the shortage
Hims & Hers proved that its telehealth model could scale profitably in 2024. Revenue grew rapidly and the company posted its first full year of net income. But the story shifted dramatically in early 2025 when the FDA resolved the semaglutide shortage. That event limited the company's ability to sell mass compounded weight loss drugs, forcing management to adapt quickly.
The bull case focuses on how well the company handled that test. Hims transitioned its weight loss users to 503A compounding based on clinical necessity, offered generic liraglutide, and secured a direct supply of branded Wegovy from Novo Nordisk. At the same time, the company aggressively expanded internationally, spending $1.15 billion to acquire Eucalyptus and rolling up brands like ZAVA and Livewell. Management also launched proactive care options, including hormone therapy and lab testing, to turn the platform into a sticky health membership.
The bear case centers on execution and margin risk. The massive scale and speed of these international acquisitions mean the company must integrate operations across the UK, Germany, Canada, Australia, and Japan. Regulators in each country have different rules. Furthermore, moving weight loss users from high margin compounded products to branded GLP-1s could pressure earnings, even if revenue continues to look strong.
Subscriptions, personalization, and vertical integration
Hims & Hers generates revenue by connecting patients with licensed healthcare providers online and selling them prescription or wellness products. Most customers sign up for recurring deliveries, making subscription behavior central to the model. The company's moat relies on brand recognition and a scalable customer acquisition engine.
The business is evolving to control more of the value chain. Hims now operates FDA registered compounding facilities, a peptide manufacturing site, and an integrated lab testing business. By controlling the supply chain, the company aims to offer personalized solutions that standard pharmacies cannot match. In late 2025, personalized offerings represented roughly 70 percent of online revenue.
The model breaks if customer acquisition costs spike, if churn rises, or if regulators limit key products. Weight loss raised revenue per subscriber because GLP-1 products cost more, but that also tied the company to a highly regulated product category. With the pivot to global markets, the company now faces the added complexity of managing direct-to-consumer health regulations in multiple foreign jurisdictions.
From reactive conditions to proactive care
Weight loss
This specialty includes compounded options, generic liraglutide, and branded Wegovy and Zepbound. It drives massive growth but faces ongoing regulatory and margin scrutiny.
Hormone therapy and lab testing
A new push into proactive care, including menopause treatments and comprehensive blood testing, designed to increase long term subscriber loyalty.
Sexual health
One of the original categories. It anchors the brand with reliable subscription revenue from treatments customers prefer to buy privately.
Dermatology and hair loss
These products fit the recurring delivery model perfectly. Personalized formulas help keep users engaged month after month.
Mental health
Digital access to mental health care adds breadth to the platform, though it must operate within strict prescribing rules.
A new geographic split
Mix reflects the updated reporting structure introduced in Q1 2026 following major international acquisitions. The company now reports United States Revenue and Rest of the World Revenue instead of Online and Wholesale.
What could break the story
Integration of global acquisitions
High impact · Medium oddsThe company spent $1.15 billion on Eucalyptus and bought other international brands like ZAVA. Integrating these operations across multiple countries brings massive execution risk and exposure to different health regulations.
Lower margin weight loss mix
High impact · Medium oddsMoving users from compounded semaglutide to branded Wegovy or Zepbound keeps them on the platform, but these branded drugs typically carry lower margins. If alternatives cost more to source, earnings quality could weaken.
Clinical necessity challenges
Medium impact · Medium oddsWith the shortage resolved, Hims relies on 503A compounding based on a provider's clinical necessity determination. Regulators or state pharmacy boards could take a stricter view on this practice, narrowing the personalized weight loss opportunity.
Vertical integration compliance
Medium impact · Low oddsOwning compounding facilities and lab testing assets gives the company control, but it brings strict manufacturing and clinical lab rules. Mistakes could lead to costly delays, enforcement actions, or facility shutdowns.
In one breath
How does Hims & Hers make money?
The company generates revenue primarily by selling prescription treatments, personalized health products, and lab testing through a recurring subscription model on its digital platform.
Why did the company change its business segments?
Following the $1.15 billion acquisition of Eucalyptus and other international brands, Hims restructured its reporting in Q1 2026 to focus on United States Revenue versus Rest of the World Revenue.
How did the FDA semaglutide shortage impact the stock?
Compounded semaglutide drove massive weight loss growth. The FDA resolved the shortage in February 2025, forcing Hims to pivot to 503A compounding and direct partnerships for branded GLP-1 drugs.
Is Hims & Hers profitable?
Yes. The company reached its first full year of profitability on a net income basis in 2024, reporting $126.0 million in net income.
